Introduction
Malignancies derived from mature T cells and natural killer (NK) cells, collectively referred to as peripheral T-cell lymphomas (PTCLs), constitute a heterogeneous group of uncommon neoplasias, accounting altogether for less than 15% of all non-Hodgkin lymphomas worldwide [1] . Although the aetiology of most PTCL subtypes is poorly understood, infections by the Epstein-Barr virus (EBV) or the human T-lymphotropic virus type 1 (HTLV-1) contribute to the development of a few entities more prevalent in Asia and Latin America where these viruses are endemic [1, 2] .
The pathological diagnosis of PTCLs is often challenging, owing to a broad morphologic and immunophenotypic variability within and significant overlaps across distinct entities; and to the lack -with few exceptions -of specific, entity-defining, genetic alterations. Conversely, the clinical features are critical to the classification of PTCLs, which are listed according to their predominant site of involvement as disseminated/leukaemic, extranodal, cutaneous or nodal entities (Table 1) [2] .
With few exceptions, PTCLs almost uniformly exhibit resistance to standard chemotherapy regimens and have a poor clinical outcome [3, 4] . The 5-year overall survival (OS) rate is as low as 30% for peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) and angioimmunoblastic T-cell lymphoma (AITL), contrasting with 70% for anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL). Most extranodal and leukaemic subtypes have an even more aggressive clinical course, with a 5-year OS ranging between 7% and 32% [3] . More effective treatment modalities are clearly needed.
Over the past years, novel insights have been gained into the pathobiology of PTCLs (reviewed in [5, 6] ). Importantly, genome-wide molecular characterization of several PTCL entities has consented to refine their diagnostic criteria and reveal novel diagnostic biomarkers [7] [8] [9] [10] [11] . The delineation of molecular subgroups has been shown to be of interest for the prognostic stratification of patients within some PTCL categories [10, [12] [13] [14] . By comparison with the molecular signatures of benign T-cell populations, gene expression analyses have also contributed to the identification of oncogenic pathways, guiding the development of novel targeted therapies [11, [15] [16] [17] [18] . Moreover, previously unrecognized recurrent genetic alterations have been recently described [19] [20] [21] . Concurrently, a number of immunotherapeutic agents are being developed or under investigation, targeting cell-surface molecules that are variably expressed across PTCL entities (reviewed in [22, 23] ). This review will focus on the most relevant of these new molecular biomarkers, by virtue of their diagnostic, prognostic or therapeutic implications (summarized in Table   2 ).
Lineage / differentiation markers
While ascribing lymphoid neoplasms to a normal cell counterpart is a major principle for their classification according to the World Health Organization (WHO) [2] , yet many PTCL entities do not conform to this criterion as their cellular origin remains poorly characterized ( Fig. 1) . This is likely due to the complexity of normal T-cell differentiation, characterized by marked functional diversity but also evidence of functional overlap and plasticity between T-and NK-cell subsets. These features might in turn account for frequent aberrations and a pronounced variability in the phenotype within distinct PTCL categories (reviewed in [24] [25] [26] ). Over the past years it has become clear that cell lineage or differentiation traits represent major determinants of the biology of these neoplasms, relevant to their classification and prognosis, and significant progresses have been achieved in the identification of the cellular derivation of several PTCL entities.
γδ T-cell lineage
Among normal mature T cells, a major distinction is based on the structure of the T-cell receptor (TCR), composed of either the αβ chains or the γδ chains. While αβ T cells (including CD4+ (mainly helper) and CD8+ (mainly cytotoxic) subpopulations) belong to the adaptive immune system featuring specificity and memory, γδ T cells participate in the innate immune responses as a first-line defence (together with NK cells) and are mostly CD4-/CD8-cells located within the skin, the mucosae and the spleen [27] .
Reflecting the paucity and distribution of normal γδ T cells, PTCLs derived from T cells of the γδ lineage (γδ PTCLs) comprise a few rare, highly aggressive, extranodal malignancies, with peculiar clinicopathologic features reflecting their cell of origin [2, 27, 28] . Hepatosplenic T-cell lymphoma (HSTL) is the prototype and the first entity initially defined by its γδ derivation (although subsequently rare cases with an αβ phenotype and a similar clinicopathologic presentation were reported [29] ). HSTL occurs predominantly in young male adults and may arise in the setting of chronic immune suppression or prolonged antigenic stimulation, particularly following long-term immunosuppressive therapy for solid organ transplantation or in children treated by azathioprine and infliximab for Crohn"s disease. The disease typically presents with hepatosplenomegaly, thrombocytopenia and systemic symptoms. Histopathology reveals a predominantly intrasinusoidal involvement of the spleen, liver and bone marrow by monotonous medium-sized T cells with a non-activated cytotoxic phenotype (see below) [30] . Genetically most cases harbour an isochromosome 7q [31] . The clinical course of the disease is rapidly progressive with an extremely dismal 5-year OS of only 7% [3] .
Among cutaneous T-cell lymphomas, it has been recognized that entities with a γδ phenotype share an aggressive behaviour and are associated with a significantly shorter survival when compared with their αβ counterparts [32, 33] , and hence primary cutaneous γδ PTCLs, irrespective of the histological pattern, are grouped under a single entity [2] . Similar cases presenting in mucosal sites may possibly be related [2, 33, 34] .
In contrast with HSTL, these non-hepatosplenic muco-cutaneous γδ PTCLs carry an activated cytotoxic phenotype (see below), and are clinically and morphologically more heterogeneous [28, 31] . Accordingly, recent GEP studies have evidenced that, while HSTLs feature a distinct and homogeneous molecular signature, non-hepatosplenic γδ PTCLs do not spontaneously cluster together in unsupervised expression analyses [35, 36] . This clinicopathologic and molecular heterogeneity favours the existence of several biologically distinct disease entities within the spectrum of non-hepatosplenic γδ PTCLs, encouraging the study of larger series of samples from different anatomic sites, to gain new insights into their pathobiological relationship and refine their classification [28, 31, [35] [36] [37] .
Until recently, expression of the γδ TCR in lymphoma samples could only be assessed by flow cytometry or by immunohistochemistry on frozen sections. As a consequence, in routinely processed fixed material the γδ phenotype was extrapolated from the negativity for the αβ TCR (recognized by the anti-βF1 antibody) [31] .
Monoclonal antibodies detecting the constant region of the TCRγ chain (CγM1) or TCRδ chain (TCRδ1) in paraffin sections have now been made available [37, 38] , and will valuably assist in the identification of these rare -and probably hitherto underdiagnosed -malignancies [28] .
NK-cell receptors (NKRs)
Although immunohistochemistry can be employed to determine the αβ versus γδ lineage of a T-cell population, it is not sufficient to assess its clonality. Instead, demonstration of T-cell monoclonality requires genetic testing, most commonly PCR assays establishing the rearrangement patterns of the TCR genes in the sample of interest. Conversely, TCR testing does not provide any information in NK-cell proliferations, since NK cells do not rearrange their TCR genes. In that setting, clonality analysis can be performed indirectly by immunophenotyping of cell-surface markers such as NK-cell receptors (NKRs). The latter include killer cell immunoglobulin-like receptors (KIRs), which recognize major histocompatibility complex (MHC) class I molecules and provide signals that regulate NK-cell functions. Since KIRs comprise multiple isoforms, a restricted KIR repertoire can be used as a surrogate marker of clonal cellular expansion. This tool has proven to be particularly useful in the evaluation of NK-cell lymphocytosis by flow cytometry, for the differential diagnosis between reactive conditions and neoplastic diseases such as chronic lymphoproliferative disorders of NK cells (CLPD-NKs) [39, 40] . Restricted KIR expression has also been demonstrated in extranodal NK/T-cell lymphomas (NKTCLs) by immunohistochemistry on frozen sections [41] .
In addition to NK-cell lymphoproliferations, T-cell large granular lymphocytic leukaemia (T-LGL) and subsets of T-cell-derived extranodal cytotoxic PTCLs (i.e. HSTL and enteropathy-associated T-cell lymphoma (EATL)) have been shown to share the expression of NKRs [39, 42, 43] , reflecting the close functional relationship between NK cells and cytotoxic T cells.
Interestingly, a peculiar KIR -namely CD158k/KIR3DL2 -is aberrantly expressed by Sézary cells, and the determination of circulating CD4+CD158k+ cells by flow cytometry has been proposed as a tool for the evaluation and follow-up of patients with Sézary syndrome [44, 45] .
Cytotoxic markers
Cytotoxicity is mediated through the release of cytotoxic granules-associated molecules, including perforin and several granzymes, and is a property shared by functional NK cells, γδ T cells and CD8+ cytotoxic T cells (of the αβ lineage), as well as several PTCL entities (summarized in Table 3 ) [2] . In addition to providing a mechanistic explanation to some manifestations of these neoplasms (e.g. preferential involvement of extranodal sites, mirroring the tropism of normal γδ T cells and NK cells; and common prominent intratumoral apoptosis), the demonstration of a cytotoxic immunophenotype may be of diagnostic or prognostic significance [2, 10, 46, 47] .
Perforin, granzyme B and T-cell intracellular antigen-1 (TIA-1) represent the most useful cytotoxic markers for diagnostic purposes, and can routinely be identified by immunohistochemistry on tissue sections. While TIA-1 is detected in both resting (nonactivated) and activated cytotoxic cells, the expression of perforin and granzyme B is a feature of activated cytotoxic cells [48] . Granzyme H, recently validated as a marker of NKTCL, can be detected by immunohistochemistry and may thus represent a novel helpful marker assisting in the differential diagnosis between NKTCLs and other cytotoxic PTCLs [11] .
Within the heterogeneous PTCL, NOS category, Iqbal et al. identified a distinct molecular subgroup, characterized by the upregulation of numerous cytotoxicity-related genes and by a significant enrichment in transcripts associated with normal activated CD8+ T cells [10] . Noteworthily, the patients within this group had an inferior survival compared to the other PTCL, NOS cases, in line with previous immunohistochemistrybased reports [46, 47] .
Follicular helper T (T FH )-cell markers
The majority of PTCLs display a CD4+ immunophenotype, with a molecular signature showing an aberrant expression of CD10, a conspicuous polymorphic reactive infiltrate, prominent arborizing vessels, increased follicular dendritic cell meshworks, and expansion of EBV-infected B blasts (reviewed in [25, 53] ). In addition, as a corollary ofand initial hint to -their T FH -cell derivation, AITL tumour cells characteristically express several T FH -cell markers, including the CXCL13 chemokine [54] [55] [56] , the cell-surface molecules PD-1/CD279 [56, 57] , ICOS [58] and CD200 [59] , the adaptor molecule SAP [60] , and the transcription factors Bcl-6 [61] and c-Maf [62] . In practice, the immunohistochemical demonstration of a T FH -like phenotype is a very helpful adjunct to support the diagnosis of AITL, particularly in morphologically challenging cases [53] .
Noteworthily, a small subset of nodal lymphomas classified as PTCLs, NOS also appears to express T FH -cell markers and may harbour a few AITL-like histologic features, questioning the criteria that define the borders between these entities [7, 63, 64] .
Interestingly, screening of PTCLs has evidenced the expression of T FH -cell markers in other PTCL subsets [65] . The latter comprise most PTCLs, NOS featuring a follicular growth pattern, i.e. the follicular variant of PTCL, NOS (PTCL-F) of which a subset harbours the t(5;9)/ITK-SYK translocation (see below) [64, 66, 67] ; and primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma [68] , a provisional entity within primary cutaneous PTCLs, often presenting as a solitary skin nodule in the head and neck area with an indolent clinical course [69] .
Cell-surface markers
Along the lines of the anti-CD20 monoclonal antibody rituximab, which has revolutionized the treatment and outcome of B-cell lymphoma patients, efforts have been undertaken to develop therapeutic antibodies targeting cell-surface molecules in PTCLs [22] . Among these, CD30 and CD52 have so far revealed as the most promising targets.
CD30
CD30 (TNFRSF8), a transmembrane glycoprotein of the tumour necrosis factor receptor (TNFR) superfamily, is involved in signal transduction via the activation of the NF-κB pathway and the mitogen-activated protein kinases (MAPKs), ultimately modulating cell growth, proliferation and apoptosis [70] . In reactive lymphoid tissues, CD30 is a nonlineage-specific activation marker expressed by scattered B and T immunoblasts. Among
PTCLs, strong and homogeneous CD30 expression is a hallmark feature of ALCLs, irrespective of their ALK gene status, and of the primary cutaneous CD30+ T-cell lymphoproliferative disorders. A subset of cases in virtually all PTCL entities may also express CD30 but at variable and generally lower levels [2, 71] .
The CD30 antigen has recently emerged as a novel therapeutic target in patients with CD30+ lymphoproliferations including ALCLs. Indeed, although most ALK+ ALCLs can be cured with first-line chemotherapy regimens, approximately 10-30% of patients are refractory or relapse after initial remission. Some of these patients may respond to salvage chemotherapy and autologous stem cell transplantation, but those who progress have a poor prognosis and treatment options at this stage are limited. ALK-ALCL, on the other hand, is associated with a more aggressive clinical behaviour and a poorer response to both primary and second-line therapeutic strategies [72] .
In the recently developed brentuximab vedotin (SGN-35), an anti-CD30 antibody has been linked to monomethyl auristatin E, a tubulin inhibitor inducing cell cycle arrest and apoptosis [73, 74] . Early clinical trials have demonstrated striking activity of this antibody-drug conjugate in the treatment of patients with relapsed or refractory CD30+ lymphomas, yielding complete remission rates of around 60% in ALCL patients, with limited toxicity (reviewed in [74, 75] ). The potential benefits of incorporating this promising agent into established chemotherapy regimens deserve to be further investigated, including as front-line therapy and possibly for patients with CD30+ PTCLs other than ALCL, such as CD30+ PTCLs, NOS, bearing a much poorer prognosis with conventional treatment approaches [72] .
CD52
CD52 is a cell-surface glycoprotein of unknown function expressed by most normal B and T cells, monocytes and macrophages, but not on haemopoietic progenitors. The presence of CD52 antigen on the surface of malignant lymphocytes has been exploited therapeutically as the target of alemtuzumab (Campath-1H), a humanized anti-CD52 monoclonal antibody inducing complement-mediated cell lysis, antibody-dependent cell cytotoxicity and apoptosis [76, 77] . Several clinical trials have demonstrated the activity of alemtuzumab against PTCLs, particularly T-cell prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphomas (CTCLs) (reviewed in [23, 77] ). In PTCL, NOS and AITL, promising responses have been observed in association with conventional polychemotherapy regimens, although frequently with major hematologic toxicity and infectious complications (reviewed in [23, 78] ).
An open question remains the delineation of the histological subtypes that could more efficiently be targeted by an anti-CD52 immunotherapy. By immunohistochemistry on paraffin sections, 30-50% of AITLs, PTCLs, NOS and NKTCLs but only a small minority of ALCLs were CD52 positive [76, 79, 80] . Conversely, by immunofluorescence on frozen tissues and/or by flow cytometry the detection rate of CD52 was generally higher, reaching 90-100% for AITLs, PTCLs, NOS and adult T-cell leukaemias/lymphomas (ATLLs), and 6-50% for ALCLs [81, 82] . GEP studies, on the other hand, have demonstrated a lower CD52 expression level in PTCLs, NOS compared to normal T cells [79] , and in CD30+ PTCLs, NOS compared to CD30-PTCLs, NOS [7] .
Surprisingly, despite this apparent heterogeneity among PTCLs, only very few studies have correlated the expression of CD52 by the neoplastic cells to the response to alemtuzumab, with divergent conclusions [83, 84] . Further studies are warranted to determine the predictive value of CD52 detection in PTCL samples, and the technique most suitable for this detection in routine settings (immunohistochemistry and/or flow cytometry).
Recurrent chromosomal translocations
Characteristic chromosomal translocations are a hallmark feature of most B-cell lymphomas, often involving the promoter of an immunoglobulin locus and a cellular oncogene which is thereby upregulated, offering both an explanation for the mechanism underlying their transformation and a useful diagnostic tool. Recurrent structural genetic alterations are also commonly observed in T-cell lymphoblastic neoplasms [5] .
Conversely, the only PTCL entity that has been long recognized in association with a specific gene rearrangement is ALK+ ALCL, carrying ALK gene rearrangements [85] .
Today this scenario is changing rapidly, as novel recurrent genetic alterations are being discovered in PTCLs, most recently as a result of next generation sequencing technologies combined with powerful bioinformatic algorithms [21] , and their list is expected to be growing over the next few years.
ALK rearrangements
The anaplastic lymphoma kinase (ALK, also designated as CD246) is a transmembrane receptor tyrosine kinase, member of the insulin receptor superfamily, whose normal expression is restricted to scattered cells in the central nervous system. Aberrant activity of the ALK kinase has been shown to contribute to oncogenesis in various lymphoid and non-lymphoid malignancies (reviewed in [86] ).
The distinguishing features of ALK+ ALCL, the best defined entity among The distinction of ALK+ ALCL from other CD30+ PTCLs is prognostically relevant, since patients with the former usually have a much better outcome than patients with ALK-ALCL or PTCL, NOS (5-year OS of approximately 70%, 50% and 30%, respectively) [72] .
From a therapeutic perspective, the recent discovery of an oncogenic EML4
(echinoderm microtubule-associated protein-like 4)-ALK translocation in a small subset of lung adenocarcinomas has boosted the efforts for developing ALK-targeting drugs.
Several small-molecule ALK inhibitors are being tested preclinically, and crizotinib (PF-02341066) has yielded promising preliminary results and limited toxicity in patients with non-small-cell lung cancers [88] . ALK+ ALCL patients, particularly when refractory to standard chemotherapy regimens, may also benefit from this novel therapeutic option and will predictably be included in future trials.
ITK-SYK translocation
The t(5;9)(q33; [20, 21, 96, 97] . As a consequence, the detection of these rearrangements by FISH may be helpful in distinguishing ALK-ALCL from other CD30+ T-cell lymphoproliferations, particularly in the skin. Indeed, among primary cutaneous T-cell lymphoproliferative disorders, FISH positivity for a 6p25.3 translocation is 99% specific for primary cutaneous ALCL [96] . As a correct diagnosis has therapeutic consequences, FISH testing for 6p25.3 rearrangements should be integrated in the diagnostic work-up in this setting.
Further investigations are needed, however, to determine the prognostic significance of these rearrangements.
Noteworthy is the report of a translocation involving the TCRA gene at the side of IRF4 (t(6;14)(p25;q11.2)) in two cases of PTCL, NOS with a cytotoxic phenotype and a peculiar, strikingly similar, clinical presentation (bone marrow and skin infiltration), suggesting that these cases may constitute a distinct clinicopathologic entity [20] .
Deregulated signalling pathways
The molecular characterization of PTCL entities has unravelled the deregulation of several signalling pathways in T-cell lymphomas in comparison with benign T-cell populations, entailing prognostic and/or therapeutic implications (reviewed in [99]).
Nuclear factor-kappaB (NF-κB)
The nuclear factor-kappaB (NF-κB) family of transcription factors has crucial functions during normal T-cell development and TCR-mediated activation, influencing T-cell proliferation and survival. Several lines of evidence indicate that deregulated NF-κB activity is involved in the pathogenesis of human cancers, including various lymphoid malignancies, by enhancing proliferation and inhibiting apoptosis [100] .
Constitutive NF-κB activation is notably induced in cells infected by the human T-lymphotropic virus type 1 (HTLV-1), via the virus-encoded oncoprotein Tax, promoting cell proliferation and oncogenic transformation [100, 101] . HTLV-1 is indeed the causative agent of adult T-cell leukaemia/lymphoma (ATLL), a mostly aggressive PTCL presenting with generalized lymphadenopathy, peripheral blood involvement and often widespread systemic disease. The peculiar geographic distribution of this malignancy (mainly observed in Japan, the Caribbean basin and Central Africa) reflects the prevalence of HTLV-1 infection in the general population [2] .
Besides ATLL, NF-κB has also been shown to be aberrantly activated in cutaneous T-cell lymphomas (CTCLs) [102] and in NKTCLs, as recently demonstrated by several GEP studies [11, 18] . NF-κB pathway engagement in NKTCLs is believed to be mediated by the Epstein-Barr virus (EBV), which is invariably associated with this destructive extranodal (prototypically nasal) cytotoxic lymphoma, most prevalent in Asia and Central-South America [2] .
Several NF-κB-blocking compounds have been shown to inhibit proliferation and induce apoptosis in malignant T cells in vitro [101, 102] . Among these agents bortezomib Other clinical trials are to be expected in the near future, and will hopefully include ATLL and NKTCL patients.
In one study the global NF-κB signature was found of prognostic value, the overexpression of NF-κB-related genes correlating with a significantly better outcome within most PTCL entities (PTCL, NOS, AITL, NKTCL and CTCL) [12] .
Although testing of the NF-κB pathway is not well codified and not yet performed routinely in PTCL samples, several proteins of the NF-κB family can be detected by immunohistochemistry and might be explored in future trials to confirm their prognostic significance [11, 12, 18] .
Spleen tyrosine kinase (Syk)
The activation of the spleen tyrosine kinase (Syk) is an essential step in the signal transduction from immune receptors, regulating early lymphocyte development. In Moreover, the Syk inhibitor fostamatinib disodium (R406) was shown to inhibit proliferation and induce apoptosis in T-cell lymphoma cell lines [95] , leading to an ongoing trial of fostamatinib in PTCL patients [23] . However, the high prevalence of Syk upregulation in PTCLs observed by Feldman et al. [94] was not found by others, who
reported Syk expression to be mostly absent [104] or limited to a subset of CD30+
PTCLs [105] , a discordance that is perhaps due to the use of different antibodies, detecting functionally distinct forms of Syk. Nevertheless, given the important therapeutic implications of targeting the activated subset of the kinase, this issue needs to be elucidated by further research.
Platelet-derived growth factor receptor alpha (PDGFRα)
Platelet-derived growth factor receptor alpha (PDGFRα) is a receptor tyrosine kinase that  The distinction of cytotoxic versus non-cytotoxic PTCLs, NOS has appeared to be biologically significant, but testing of larger series is required to establish its clinical relevance.
 Next-generation genome-wide technologies will be disclosing novel oncogenic mechanisms, predictive markers and therapeutic targets in the near future, opening the way for individually tailored treatments for PTCL patients as well. ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; EATL, enteropathy-associated T-cell lymphoma; EBV, Epstein-Barr virus; HSTL, hepatosplenic T-cell lymphoma; NKTCL, extranodal NK/T-cell lymphoma; non-HS, non-hepatosplenic; NOS, not otherwise specified; PTCL, peripheral T-cell lymphoma; TCL, T-cell lymphoma.
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* Activated cytotoxic phenotype: expression of perforin and/or granzyme B in addition to TIA-1; nonactivated cytotoxic phenotype: expression of TIA-1 only.
Fig. 1.
Overview of normal T-cell and NK-cell differentiation and putative histogenetic derivation of the major PTCL entities (reproduced with permission from de Leval et al. [25] ).
AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; HTLV1, human Tlymphotropic virus type 1; NK, natural killer cell; NOS, not otherwise specified; PTCL, peripheral T-cell lymphoma; TCL, T-cell lymphoma; TFH, follicular helper T cell; Treg, regulatory T cell.
